Quartz·1 min read·medium
Novo Nordisk is suing Eli Lilly over ads it says mislead consumers on weight loss drug efficacy
✦AI Summary
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging that the company's marketing for Zepbound and Mounjaro uses outdated data. Novo claims these advertisements mislead consumers regarding the comparative efficacy of their weight loss drugs.
Novo says Lilly's TV and social media campaigns cite outdated trial data to make Zepbound and Mounjaro look more effective than rival injections
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in